Exploratory study examines symptom progression in GBA1 variant carriers versus non-carriers, suggesting rapid decline in some symptoms.
Introduction An association between severe GBA1 variants and the progression of non-motor symptoms in PD has been reported, but the role of Parkinson’s-risk (PD-risk) GBA1 variants is less clear. Methods We assessed symptom progression in individuals with severe and PD-risk variants compared to non-carriers. We analyzed longitudinal data from 726 individuals with typical PD, including 22 carriers of severe GBA1 variants and 47 carriers of PD-risk GBA1 variants. Results The findings were not significant after adjusting for Bonferroni correction; however, linear mixed models analyses showed that at a nominal significance level of 5%, carriers of PD-risk or severe variants were associated with faster cognitive decline compared to non-carriers. Moreover, carriers of PD-risk variants were associated with faster worsening of apathy, quality of sleep, tremor, and non-motor symptoms [Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS I)] compared to non-carriers; however, we did not observe this tendency in individuals with severe variants. Discussion The exploratory study suggests associations between PD-risk variants and a more rapid disease progression among carriers compared to non-carriers. Nevertheless, the findings should be interpreted cautiously and require confirmation in an independent cohort before any reevaluation of their pathologic relevance.
No takes yet. Share an insight, caveat, or question.
Hanff et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: